Sabby Management’s Minerva Neurosciences NERV Stock Holding History

Sabby Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,750	Closed	-$388K	–	325
2016 Q2	$388K	Buy	+4,750	New	+$302K	0.02%	221

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sabby Management's NERV Position: Q3 2016 in Review

Sabby Management sold out of Minerva Neurosciences (NERV) in Q3 2016, closing a stake of 4,750 shares — an estimated $388K sold.

Sabby Management first reported a position in NERV in Q2 2016 and held it in 1 quarter. The position peaked at $388K in Q2 2016. 67 funds tracked by Wall St. Rank hold NERV as of Q3 2016.

Sabby Management reported no remaining Minerva Neurosciences position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 4,750 Minerva Neurosciences shares in Q3 2016, an estimated $388K.
Sabby Management first reported a position in Minerva Neurosciences in Q2 2016 and held it in 1 quarter.
Sabby Management's Minerva Neurosciences position peaked at $388K in Q2 2016.
67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.